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Abstract 
A common purpose of microarray experiments is to study the variation in gene expression across the 
categories of an experimental factor such as tissue types and drug treatments. However, it is not uncommon 
that the studied experimental factor is a quantitative variable rather than categorical variable. Loss of 
information would occur by comparing gene-expression levels between groups that are factitiously defined 
according to the quantitative threshold values of an experimental factor. Additionally, lack of control for 
some sensitive clinical factors may bring serious false positive or negative findings. 
In the present study, we described a bootstrap-based regression method for analyzing gene expression 
data from the non-categorical microarray experiments. To illustrate the utility of this method, we applied it to 
our recent gene-expression study of circulating monocytes in subjects with a wide range of variations in bone 
mineral density (BMD). This method allows a comprehensive discovery of gene expressions associated with 
osteoporosis-related traits while controlling other common confounding factors such as height, weight and 
age. Several genes identified in our study are involved in osteoblast and osteoclast functions and bone 
remodeling and/or menopause-associated estrogen-dependent pathways, which provide important clues to 
understand the etiology of osteoporosis. 
Availability: SAS code is available from the authors upon request. 
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Introduction 
DNA microarrays are a powerful tool to provide a comprehensive picture of cell function as they can 
assay expression of tens of thousands of genes simultaneously. A typical microarray experiment may involve 
a comparison between disease and normal tissues, or a comparison between a strain grown under an 
experimental treatment and the same strain under a control condition. Various fold-change algorithms or t 
statistics were used for statistical analyses of this kind of two-sample experiment designs (1, 2). More 
complex experimental designs, in contrast, may comprise more than two samples as characterized by their 
genotypes, environments or developmental stages (3-5). A common purpose of these microarray experiments 
is to study the variation in gene expression across the categories of an experimental factor such as the above 
mentioned tissue types and drug treatments. However, an experimental factor is often a quantitative variable 
rather than a categorical variable. Loss of information would occur by comparing gene-expression levels 
between groups that are factitiously defined according to quantitative threshold values of an experimental 
factor. Additionally, lack of control for some sensitive clinical factors such as height, weight and age may 
yield serious false positive or negative findings.  
 
In the present study, we described a bootstrap-based regression method for analyzing DNA 
expression data from the non-categorical microarray experiments. Bootstrap is an interesting method to select 
covariables in multivariable models. It allows increasing internal validity of models (6) and has been used 
widely in biology (7, 8). To illustrate the utility of this method, we applied it to our recent gene-expression 
study of circulating monocytes in subjects with a wide range of variations in bone mineral density (BMD). 
BMD, a quantitative clinical phenotype, is a major risk factor for osteoporosis in the elderly especially in the 
postmenopausal women (9). BMD has a large genetic determinant while is significantly affected by height, 
weight, age, and life-style factors such as smoking, exercise and alcohol consumption (10-14). Menopause is 
a major physiological event associated with accelerated bone loss in females (15). Using the proposed 
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method, we attempted to identify differentially expressed genes associated with BMD variation and 
menopausal events while controlling other confounding factors such as height, weight and age.  
Methods 
Subjects and measurement 
The study subjects came from an expanding database being created for genetic studies of osteoporosis, 
which are underway in the Osteoporosis Research Center of Creighton University. Since our major goal is to 
find genes related to osteoporosis, the exclusion criteria to exclude diseases or medications known to affect 
bone metabolism were used. Given that monocytes were used in this study, the additional exclusion criteria 
were also implemented to exclude those diseases/conditions, which may lead to gene expression changes of 
blood monocytes. All the exclusion criteria were detailed earlier by Liu et al. (16). 
 
We analyzed gene expressions of blood monocytes using Affymetrix HG-U133A GeneChip®, 
containing probes for 14,500 genes. The raw fluorescence intensity data within CEL files were processed 
with Robust Multichip Average (RMA) algorithm (17), as implemented with R packages from Bioconductor 
(www.bioconductor.org). Blood monocytes were obtained from 19 otherwise healthy women, each woman 
had total hip BMD, lumbar spine BMD (L1-L4), weight and height measurements, and completed a 
questionnaire with age, menopause status and years since menopause for postmenopausal women. Hip and 
spine BMD were measured with Hologic 4500 dual energy X ray absorptiometry (DXA) scanners (Hologic 
Corporation, Waltham, Massachusetts, USA). The machine was calibrated daily. The coefficient of variation 
(CV) values of the DXA measurements for BMD is 0.9%.  Weight was measured using a calibrated balance 
beam scale; height was measured using a calibrated stadiometer. Table 1 presents the basic characteristics of 
the study subjects.  
 
Statistical methods  
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Let ny be the expression level for gene n and x be a vector of experimental factors of interest (such as 
BMD, menopause status and years since menopause) and potential clinical covariates (such as height, weight 
and age). Then, the model for a multiple linear regression takes the form, 
  xyn  
where   is regression intercept,   are regression coefficients and   is residual. Note that the years since 
menopause for premenopausal women were set to zero. The stepwise method was used for choosing 
independent variables in this multiple regression model. The selection p value for both inclusion and 
exclusion of a variable in the regression model was set as 0.05. In our preliminary data, there were 6363 
genes for each of which at least one independent variable was selected in the model. To obtain a robust list of 
important genes in relation to the independent variables, 1000 bootstrap resampling was used to estimate 
bootstrap frequencies of each variable selected in the regression model for each gene. We observed that the 
random sampling errors are very low when using 1000 bootstrap samples. If a variable has strong bootstrap 
support (frequency greater than 80%), this variable is regarded to be related with the tested gene. Although 
80% bootstrap frequency was an empirical threshold, we believe this threshold is very stringent for choosing 
BMD-related genes. All statistical analyses were implemented in the SAS 8.0e (SAS Institute, Cary, N.C., 
USA).  
 
Results and Discussion 
Using the standard of bootstrap frequency greater than 80%, we found 75 hip BMD-related genes, 
173 spine BMD-related genes, 221 menopause-related genes, and 139 years since menopause-related genes 
(Supplemental Table 1).  
 
Among BMD-related genes, 37.4% of them were associated with cellular protein metabolisms based 
on the inference of gene ontology (GO). Particularly, BMPR1A, TNFRSF10C, TNF, FIP2, TGFBR1, CCL11, 
PTHB1, CXCL3 and MTHFR are potentially involved in osteoblast and osteoclast functions and bone 
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remodeling according to the currently available literatures. BMPR1A is bone morphogenetic protein receptor 
(BMP), type 1A. A recent mouse mutation study demonstrated essential and age-dependent roles for BMP 
signaling mediated by BMPR1A in osteoblasts for bone remodeling (18). BMPR1A is located on the human 
chromosome 10q22.3. Klein et al. reported two mouse QTLs for whole body BMD in the genomic regions 
homologous to human 10q21-24 and 10q23-26 (19, 20). TNFRSF10C, TNF and FIP2 are members of tumor 
necrosis factor (TNF) superfamily. TNF is a proinflammatory cytokine that promotes osteoclastic bone 
resorption and inhibits osteoblast differentiation (21-23). CCL11 is another proinflammatory cytokine 
important to osteoarthritis. The CCL11 expresses eotaxin-1 induced by treatment with interleukin-1β and 
TNF- and plays an important role in cartilage degradation in osteoarthritis. TGFBR1 is a transforming 
growth factor (TGF) beta receptor whose expression is important in mediating 1, 25(OH) 2D3-associated 
changes in the growth rate of osteoblasts (24). PTHB1 (parathyroid hormone-responsive B1) is 
downregulated by parathyroid hormone in osteoblastic cells, and therefore, is thought to be involved in 
parathyroid hormone action in bones. CXCL3 is a chemokine (C-X-C motif) ligand. CXCL3 is potentially 
involved in chemokine activity based on the NCBI GO inference, which is known to participate in bone 
monocyte recruitment (25, 26). MTHFR (5,10-methylenetetrahydrofolate reductase) can affect the 
methylation of homocysteine to methionine and high serum homocysteine concentrations have adverse 
effects on bone (27, 28). A polymorphism of the MTHFR gene, C677T, which causes an alanine to valine 
substitution and gives rise to a thermolabile variant of the MTHFR protein with reduced activity (29), was 
associated with elevated levels of circulating homocysteine (30) and lumbar spine BMD (31). During the past 
two years, a number of association studies appeared with regard to its relevance to osteoporosis (32-35). It is 
worth noting that several osteoblast-related genes such as BMPR1A and PTHB1 were found in circulating 
monocytes which are early precursors of osteoclasts. Bone loss in osteoporosis is due to the persistent excess 
of bone resorption over bone formation. Osteoblasts play a central role in bone formation by synthesizing 
multiple bone matrix proteins, while they also regulate osteoclast maturation by soluble factors and cognate 
interactions, resulting in bone resorption. For example, while FGF-2 induces RANKL expression by 
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osteoblasts, it also inhibits osteoclast differentiation directly by interfering with the action of M-CSF (36). 
Thus, osteoclast differentiation, formation, and, to a lesser degree, activation depend upon the proximity and 
products of the osteoblast. Therefore, it is not unexpected to identify osteoblast-related genes differentially 
expressed in monocytes in the present study. These genes may regulate the balance between osteoblast and 
osteoclast activity that is important for bone remodeling and health.  
 
Among genes that are related to menopausal status or years since menopause, several are upstream 
and downstream targets of estrogen receptors, including MAPK1, U29725, laminin 2, laminin β1, PLAU, 
PRKD3, ALPP, ADAM2, ADAM21, ADAM22, ADAMTS2, ADAMTS6, TNFSF13, TNFRSF13B, TNFRSF25, 
TRADD, TNFAIP6 and IL22R. The expression changes of these genes may be due to the fact that ovaries 
reduce and stop producing estrogen in postmenopausal women. In our data, the status of menopause had 
effects on MAPK1 gene expression (bootstrap frequency=83.5%) and years since menopause affected 
U29725 (MAPK7) gene expression (bootstrap frequency=93.5%). Estrogen can activate the MAPK family 
member extracellular regulated kinase-1 (ERK-1). Increases in ERK activation coincided with increased ER-
 phosphorylation. Reduced availability of this pathway when estrogen levels are reduced could explain 
diminished effectiveness of mechanically related control of bone architecture after the menopause (37). Two 
laminin genes, laminin 2 and laminin β1, were detected to be associated with menopausal status and years 
since menopause, which were potentially involved in maintenance of estrogen receptor alpha expression (38). 
PLAU (urokinase-type plasminogen activator) was shown to be downregulated by ovariectomy but restored 
with estrogen during fracture healing (39). PRKD3 is a member of protein kinase C (PKC) family. Recent 
data revealed a direct PKC-c-Src-ER interaction, which may be crucial in the modulation of estrogen 
responsiveness and the differentiation process in osteoblasts (40). ALPP (alkaline phosphatase) is a bone 
formation marker. Bone alkaline phosphatase was significantly increased in postmenopausal women (41). 
Interestingly, we found three genes (ADAM2, ADAM21 and ADAM22) that encode a member of the ADAM 
(a disintegrin and metalloprotease domain) family and two genes (ADAMTS2 and ADAMTS6) that encode a 
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member of the ADAM with thrombospondin motifs (ADAMTS) protein family. Both ADAM and ADAMTS 
gene families have been shown to play a role in bone osteoblast function in several recent studies (42-45). It 
has been suggested that one of the mechanisms by which estrogen protects against postmenopausal 
osteoporosis is by modulating the production of cytokines, such as tumor necrosis factors (TNF), interleukin-
1 (IL-1) and interleukin-6 (IL-6), in the bone microenvironment (46). In our data, five TNF superfamily 
genes (TNFSF13, TNFRSF13B, TNFRSF25, TRADD and TNFAIP6) and one interleukin cytokine (IL22R) 
were associated with menopausal female events.  
 
Figure 1 shows hierarchical clustering for 19 samples using differential expression associated with 
BMD variation, menopausal status, and years since menopause. According to the results of the cluster 
analysis, women with hip BMD value greater than 0.9 were classified into one group and those smaller than 
0.9 were classified into another group. Pre- and postmenopausal women also had quite distinct patterns of 
gene expression and therefore were clearly clustered into two well-defined groups. Based on the expression 
data associated with years since menopause, those women who have not experienced or recently experienced 
menopause were classified into one group, while those women who have experienced menopause for a long 
time (at least more than 4 years) were classified into another group.  
 
Conclusions 
In summary, we described a bootstrap-based regression method for handling expression data from the 
non-categorical microarray experiments. This method allows a comprehensive discovery of gene expressions 
associated with osteoporosis-related traits while controlling other common confounding factors such as 
height, weight and age. We prioritized a small list of candidate genes for future confirmation studies in terms 
of their functional relevance to osteoblast and osteoclast functions and bone remodeling and/or menopause-
associated estrogen-dependent pathways. These gene expression data provide important clues to understand 
the etiology of osteoporosis.  
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Figure legend 
Figure 1 Hierarchical clustering for 19 samples using differential expression associated with (A) BMD 
variation, (B) menopausal status, and (C) years since menopause. Red indicates upregulated genes, and green 
represents down-regulated genes. At the top of panel A, the numbers represent hip BMD value of each 
woman. At the top of panel B, the letter “pre” represents premenopausal women and “post” represents 
postmenopausal women. At the top of panel C, the numbers represents years since menopause for each 
woman. Note that the years since menopause for premenopausal women were set to zero.  
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Table 1 Basic characteristics of the study subjects 
 
 
 
Trait Mean ± SD Range 
Hip BMD (g/cm
2
) 0.932 ± 0.169 0.721-1.339 
Spine BMD (g/cm
2
) 1.023 ± 0.234 0.748-1.428 
Age (years) 51 ± 2.54 47-55 
Height (cm) 167.0 ± 7.5 154.8-177.4 
Weight (kg) 77.0 ± 21.7 48.7-126.1 
Years since menopause (years) 6.4 ± 4.7 1-15 
MAN1B1
LONP
PRKCZ
PSCD1
SEC23B
---
SMARCA4
DOCK6
MCM2
KIAA1026
ANK2
MAPK7
HNRPD
PHF15
PGPL
GPR57
PRDM10
SULT2A1
FLJ12788
CRYL1
LOC160313
MAP2K7
IGKC
DERP6
---
AKAP6
HP
XPO6
PGRMC2
KCNV1
UBE2L3
FLJ21940
FLJ20489
PACS1
PRKCN
BUB1
TIMM50
KCNJ4
TLL2
TRADD
KPNB1
TNFRSF25
ZNF44
THAP4
IGHM
MGC4809
IGHG1
IGLC1
TOSO
IGHG1
ST7L
STAR
BHLHB3
DXS1283E
SMAD6
RPL3L
MUC5B
C22orf19
SPDEF
CHD3
MASP1
OSMR
EAP30
SOX13
CAPN9
H2AFY
ADAM21
ALDH6A1
TDGF1
TWIST1
SIRT5
CA6
G22P1
CTH
ALPP
DKFZp547G183
TDRD4
NOVA1
---
EIF4G2
---
AP4S1
FLJ11301
TED
FLJ20477
FLJ10547
MBL2
AMPD3
XPO1
---
CLDN1
MTX1
---
GRIK5
---
HNRPM
TNFAIP6
---
MASP1
GPR157
CADPS2
FARSLA
RAP2B
AQP6
APG12L
TIMM17A
GAGE5
LRRN5
KIAA0669
HBXAP
SYNJ2
STAP2
HOMER2
GJB3
---
DTNA
KCNJ8
EVC
C11orf9
KIAA0643
TOM1L1
PLAU
FZD6
LOC377064
RGS13
SEPP1
SEMA3D
RNF14
FLJ23861
WARS2
SLC28A3
LAMB1
SLC14A2
PPL
STIP1
DPP4
CES1
DIRAS2
KIAA0117
0 0 0 0 0 1 2 0 3 0 0 0 3 11 11 15 8 6 4
IL22RA1
PLAC8
PPIA
ADAM2
PMS2L2
MTAP
GCG
UGCG
C4orf10
SSX1
CDIPT
POLA2
CSNK2A1
CORO2A
SLC7A5
ITSN1
LOC339229
C10orf7
FLJ21511
BRAP
SBNO1
HBG1
FLJ22659
DAPK2
C9orf36
PTPRB
PPAP2B
ST7L
BIRC1
MAGEE1
FCGR1A
FCGR1A
TTC3
LAMA2
---
ADRA1B
NID2
SSRP1
SLC8A1
PRO2964
ACTN2
UPK3B
ADAM22
FLJ12151
C1GALT2
NCR3
MRPS18B
SNX1
METAP2
DDR1
DEFB4
NR3C2
HESX1
PHKB
KIAA1069
UBB
CACNA1G
AIF1
ASCL2
MKRN4
LRRFIP1
NINJ2
RNASET2
EIF2S1
KIAA1361
ZNF16
THADA
PGF
POLR1B
NDUFA9
KIAA0773
TCL6
LGALS13
MDH1
ALS2CR3
TM4SF13
IRF8
NQO2
FNDC3
GPC6
BCAS2
UBE2I
MYO6
FLJ21369
BHLHB3
ARHGAP6
BBP
C14orf32
MAPK1
LOC138046
FLJ23091
NF2
DLG7
PTPN11
TULP1
U2AF2
C21orf108
FSCN1
SRISNF2L
ACADSB
FLJ20509
PPP1R3D
TRO
DKFZp547I014
SLC27A6
RBM5
UPF3A
PAICS
MPPE1
CD44
CLDN15
HNRPDL
PTPRR
NF2
CBFA2T2
KIAA0514
TEB4
MTMR4
DCLRE1B
PLK4
---
TNFRSF13B
SCA7
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ALOX15B
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HPGD
---
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SLC2A10
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---
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PHF7
ADAMTS6
C9orf77
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FLJ22843
SGCD
LYPLA3
SLC43A3
PASK
SERPINB10
FLJ10902
CLC
OR3A2
UBE2H
OK/SW-cl.56
PTD008
---
EN2
DDX28
CG018
SLC2A1
FLJ20257
NICE-4
C6orf35
FLJ20898
TNFSF13
NFX1
ASTN2
SSTR5
G3BP
---
CHN2
ELF2
FBLN2
FMO3
LAD1
COL4A4
LYZ
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MYO1B
SNRPA1
ZHX2
MERTK
ZNF204
RFC1
TRIB2
NRP2
LY6G6E
CCNT2
WDR4
RAB2
OPTN
UBPH
TPR
FLJ10808
ZNF473
PFN2
RYK
GFER
SAP30
MS4A2
---
SAMSN1
BMPR1A
EDNRB
CAV2
SCIN
FLJ30656
ZNF237
---
MRAS
NET1
SLC27A2
RAB32
AR
OSBPL3
U2AF2
C18orf10
TMLHE
CDC25C
SNIP1
TGFBR1
RGS16
LOC81558
RDX
JAK2
PCTK2
EIF2AK3
SMC4L1
TRA1
PSMC2
SEC23B
PPP1CC
TRIM8
RBM5
NUP107
MEG3
RNASE3L
NR3C1
BUB3
FLJ11011
RIMS3
PDE4B
GATM
EFNA1
KNS2
RBL1
HERC2
DDX27
ATRX
HNRNPG-T
DC50
CXCL3
ITPR1
LGALS8
RASSF3
FLJ10652
NCK1
BCLAF1
ALDH1A1
ABI1
MARCO
FLJ21908
HNRPU
ENDOG
---
ABHD5
ALS2CR3
LMAN2L
SLC11A2
NCBP1
ABCA1
EIF4A2
hnRNPA3
SIP
CCT2
B1
HNRPA3
HNRPA3
KIAA0436
TOMM20
GRSF1
MRPS28
CCT7
ELOVL5
PAI-RBP1
MO25
FBXO11
FUSIP1
MGC21416
HMGN3
NR3C1
SMARCA4
ICSBP1
PPP2R5E
PC4
ATP5F1
DDX39
TRAPPC3
H41
DLD
HNRPA1
EIF2B1
C15orf15
RUNX1
NOTCH2
SMC4L1
SENP6
ZNF451
HHLA1
TNF
NRP2
CASP4
SF3B2
MDC1
CCL11
TNFRSF10C
TMEM24
RORC
FLJ13544
PRKAG2
SLC2A8
SLC7A8
PDE4DIP
CHEK1
CSPG5
BRPF1
KIAA0556
HCK
ZG16
---
GPM6B
ADAM19
SARM1
CENPA
LZTR1
KIAA0676
FTL
PRG-3
MMP24
SPUF
---
HSPA6
HSPA6
ARSE
C4BPA
ZNF235
SHOX2
DTR
PADI1
PCDHGC3
PPP1R15A
LYPLA2
ANAPC13
EPHB4
PPT2
TSC1
ARMC4
LY6G5C
CYLC2
SSB1
C19orf22
INHA
ARF5
GGT1
POLQ
CACNA1B
NPM3
DOM3Z
TIMP2
HMG20B
PTPN18
GGA1
SDAD1
NUCB1
RXRA
CLTB
MTHFR
---
MAN2C1
TNS
ASAHL
DDX11
ANGPT1
ICOSL
BANF1
PPIA
PAK2
CD99
MRPL52
B1
DOK1
BIRC5
HIST1H2BN
NRL
FLJ20477
TAGLN2
CYP2C8
KIAA0101
LOC55924
SERPINA1
MYL4
MAPK8IP3
GPLD1
NFASC
UGT2B28
PURA
PPIG
ATP6V1F
LYPLA2
PLVAP
FLJ22318
RGS6
TBR1
WDR10
CPR8
FN1
KIAA0090
CLEC2
LOC55831
MAGEL2
SCN2A2
CSNK2B
MID2
ODZ3
NCDN
PSKH1
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